Shares of BriaCell Therapeutics Corp. (CVE:BCT – Get Free Report) traded down 3.8% during trading on Tuesday . The stock traded as low as C$10.60 and last traded at C$10.60. 3,402 shares traded hands during trading, a decline of 73% from the average session volume of 12,671 shares. The stock had previously closed at C$11.02.
BriaCell Therapeutics Stock Performance
The stock has a market cap of C$168.68 million and a P/E ratio of -28.19. The company has a debt-to-equity ratio of 0.05, a current ratio of 129.63 and a quick ratio of 128.68. The stock’s 50 day simple moving average is C$10.60 and its two-hundred day simple moving average is C$10.60.
About BriaCell Therapeutics
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
Recommended Stories
- Five stocks we like better than BriaCell Therapeutics
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
